Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Introduction Thanks to the results of DECISION and SELECT trials, sorafenib and lenvatinib are the only MKIs approved by both the U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA) for the first-line treatment of
Search for other papers by Xian Qiu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China
Search for other papers by Ri Sa in
Google Scholar
PubMed
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Hao Fu in
Google Scholar
PubMed
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
, including chemotherapy and external beam radiation therapy, remains limited in these challenging settings. In recent years, tyrosine kinase inhibitors (TKIs) such as sorafenib and lenvatinib have highlighted new therapeutic options for the treatment of
Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
What Is Known About This Topic? Several side effects have been described with the use of tyrosine kinase inhibitors like sorafenib. Nonetheless, only 9 cases of pancreatitis related to sorafenib treatment have been described, all of them
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
objective of inhibiting the MAPK pathway and angiogenesis [ 3 ]. Sorafenib, a TKI which inhibits VEGFR 1, 2, and 3, RET (including RET/PTC), RAF (including BRAFV600E), and platelet-derived growth factor receptor beta (PDGFRβ), has already been evaluated in
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
cabozantinib OR crizotinib OR dasatinib OR erlotinib OR imatinib OR ibrutinib OR lapatinib OR midostaurin OR neratinib OR nilotinib OR pacritinib OR pazopanib OR ponatinib OR regorafenib OR sorafenib OR sunitinib OR vandetanib OR ziv-aflibercept OR gefitinib OR
Search for other papers by Daniela Dias in
Google Scholar
PubMed
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Helder Simões in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
MKIs sorafenib and lenvatinib for the treatment of metastatic progressive differentiated thyroid cancer (DTC) of follicular origin. These drugs now play a major role as first-line targeted therapy for such tumors. Progression-free survival was 10
Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Search for other papers by Lucy Wall in
Google Scholar
PubMed
Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
deemed unsuitable for surgery, limited alternative options were available. Sorafenib and lenvatinib both showed a prolonged progression-free survival advantage in patients with radioactive iodine-refractory differentiated thyroid cancer (DTC
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Jan Smit in
Google Scholar
PubMed
.g. sorafenib and lenvatinib. The efficacy of both drugs has been demonstrated in phase III studies (DECISION study for sorafenib [ 13 ] and SELECT study for lenvatinib [ 14 ] and has been confirmed in “real-life” studies [ 15 - 19 ]. Although criteria for
Search for other papers by Marine Sitbon in
Google Scholar
PubMed
Search for other papers by Porhuoy Chou in
Google Scholar
PubMed
Search for other papers by Seydou Bengaly in
Google Scholar
PubMed
Search for other papers by Brigitte Poirot in
Google Scholar
PubMed
Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed
Search for other papers by Laure Deville in
Google Scholar
PubMed
Search for other papers by Atanas Pachev in
Google Scholar
PubMed
Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed
Search for other papers by Clement Dumont in
Google Scholar
PubMed
Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed
patient refused vandetanib treatment. Similarly, another team showed a rapid response with sorafenib, but sorafenib was not approved for MTC ( 10 ). Here, we report successful treatment of Cushing’s syndrome with RET-targeted therapy in a patient with
College of Medicine, Yonsei University, Seoul, Republic of Korea
Search for other papers by Jihwan Yoo in
Google Scholar
PubMed
Search for other papers by Hee Jun Kim in
Google Scholar
PubMed
Search for other papers by Seok Mo Kim in
Google Scholar
PubMed
Search for other papers by Hun Ho Park in
Google Scholar
PubMed
number of brain metastases). Progressive thyroid cancer was preferentially treated with RAI therapy; TKIs, including sorafenib or lenvatinib, were administered when the cumulative RAI dose exceeded 600 mCi. Following the confirmation of brain metastasis